BAX and acute myeloid leukemia: On the other hand, Reyna et al. developed a pharmacologically optimized Bax activator called BTSA1, which suppressed human AML xenografts, overcoming apoptosis resistance, thus suggesting that direct Bax activation is a possible treatment strategy in AML [44].